Bifen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bifen

Understanding Bifen

Bifen is a synthetic insecticide and acaricide belonging to the pyrethroid chemical family. It is utilized primarily for the management of a broad spectrum of pests in agricultural, residential, and commercial settings. The compound is designed to mimic the naturally occurring insecticidal properties found in chrysanthemum flowers, though it is engineered to be more stable and longer-lasting in various environments.

Primary Uses

This substance is frequently employed to control populations of insects and mites that can damage crops or infest structures. Common applications include:

  • Agricultural Management: Protection of crops such as corn, cotton, and various fruits and vegetables from feeding insects.
  • Structural Pest Control: Prevention and management of termite infestations in wood and soil.
  • Lawn and Garden Maintenance: Control of turf pests, including ants, chinch bugs, and ticks.

Mechanism of Action

Bifen functions by targeting the nervous system of insects. It interacts with the sodium channels in nerve cells, preventing them from closing normally. This interference results in a continuous flow of sodium ions, leading to overstimulation of the nervous system, paralysis, and the eventual death of the target organism.

Physical Properties

In its technical form, Bifen is typically an odorless, off-white solid. Because it has very low solubility in water, it is often formulated as an emulsifiable concentrate or as granules to facilitate application. Its chemical stability allows it to remain effective on treated surfaces for extended periods, providing residual control against pests that come into contact with the treated area.

Regulatory References

  1. National Institutes of Health
  2. NIH: MedlinePlus Drug Information

What side effects are possible with Bifen?

Possible Side Effects and Safety Information

The safety profile of Bifen, an NSAID, is characterized primarily by its effects on the Gastrointestinal (GI) and Cardiovascular (CV) organ systems, as documented in official regulatory labeling. Adverse reactions are classified by frequency, ranging from common to very rare.


Common and Expected Regulatory Findings

Adverse effects officially classified as common typically involve the digestive and nervous systems. These frequently reported events include dyspepsia (indigestion), nausea, vomiting, abdominal pain, and headache or dizziness.


Serious Adverse Reactions

The most serious adverse reactions are rare but clinically significant, reflecting the high-level safety constraints of the medicine class. Regulatory authorities note an increased risk of serious arterial thrombotic events, such as myocardial infarction (heart attack) and stroke. Similarly, serious GI events, including bleeding, ulceration, and perforation of the stomach or intestines, are documented as potential, sometimes fatal, risks. Severe cutaneous adverse reactions (SCARs), suchemia as Stevens-Johnson Syndrome (SJS), are also listed as very rare but documented adverse events.


Contextual Safety Patterns

Official labeling specifies that the risk of serious cardiovascular thrombotic events is associated with long-term use and high doses. Furthermore, the safety profile is subject to population-specific considerations. Older adults face a greater risk of serious GI and renal adverse events. Bifen is explicitly contraindicated during the late stage of pregnancy (from approx30 weeks gestation) due to documented risks to the fetus. The medicine is also restricted in individuals with severe, pre-existing conditions like heart failure, renal failure, or active gastrointestinal ulceration.

Overdose and Emergency Response

Overdose and When to Seek Help: Bifenthrin (Bifen)

This information is strictly based on official government regulatory documents and safety data regarding acute overexposure to Bifenthrin formulations.


Documented Acute Manifestations

Overexposure, especially through skin contact, may cause localized signs such as transient tingling, burning, or numbness (paraesthesia), often resolving within hours. Ingestion or inhalation may lead to systemic symptoms including nausea, vomiting, headache, dizziness, and throat irritation.


Life-Threatening Outcomes

Severe ingestion is associated with potentially life-threatening outcomes, including convulsions (seizures), severe muscle twitching (fasciculations), and loss of consciousness. For products containing petroleum-based solvents, there is a risk of aspiration pneumonia if the patient vomits.


Required Emergency Actions

IMMEDIATELY call a Poison Control Center or doctor for treatment advice if the product is swallowed. If an exposed person is not breathing or exhibits severe symptoms like seizures or loss of consciousness, call 911 or emergency services. Medical treatment is symptomatic and supportive, as no specific chemical antidote is currently documented in official prescribing notes. Medical staff are advised to avoid administering oils or fats, as these may enhance product absorption.

Therapeutic Uses of Bifen

Bifen's primary role is to provide symptomatic relief across key therapeutic domains where discomfort, inflammation, and fever create noticeable interference with daily stability. The medication is considered relevant for addressing conditions that cause symptoms related to physical discomfort, systemic imbalance, and inflammatory states.

Symptom Management and Conditions

Bifen is commonly used across conditions presenting with systemic or localized discomfort caused by inflammatory or irritative processes, such as managing the pain and stiffness of rheumatoid arthritis and osteoarthritis. It helps address symptom clusters associated with acute episodes, including pain from sprains, muscle strains, dental procedures, headaches, and acute fever related to the common cold or flu. Furthermore, it is relevant for easing the intense, disruptive manifestations of primary dysmenorrhea (menstrual cramping).

“Bifen provides supportive relief when symptoms interfere with routine activities, helping to maintain a sense of stability when discomfort becomes more noticeable.”

It contributes to improved comfort during periods of heightened symptoms, offering supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Inflammation Bifen may assist with maintaining functional stability for patients with active joint and soft tissue conditions by helping to ease stiffness and localized swelling.

Regulatory References

  1. Ibuprofen: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Bifen?

The population eligibility for Bifen, which contains the active ingredient Ibuprofen, is strictly defined by regulatory documents, distinguishing between permitted, restricted, and contraindicated groups.

Populations for Whom Use is Contraindicated

Bifen must not be used by individuals with a confirmed hypersensitivity to Ibuprofen, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID). Use is also absolutely prohibited in patients with a history of active or recurrent gastrointestinal bleeding or peptic ulceration.

Contraindications related to pre-existing disease include severe renal failure, severe hepatic failure, and severe heart failure (NYHA Class IV). Furthermore, Bifen is contraindicated for the treatment of pain following coronary artery bypass graft (CABG) surgery and during the third trimester of pregnancy.

Age and Condition-Based Restrictions

Population Group Regulatory Status
Children Permitted for ages typically mathbfgeq 6 months, dependent on weight and specific formulation.
Older Adults Use requires caution; lowest effective dose for shortest duration due to increased risk of adverse events.
Mild to Moderate Organ Impairment Restricted use with caution and careful monitoring of renal and hepatic function.
First/Second Trimester of Pregnancy Avoided unless necessary; use the lowest dose for the shortest time.

Standard labeled use is permitted for adults and eligible pediatric populations who do not meet any of the defined contraindication criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Bifen (Ibuprofen) around combinations that are formally contraindicated and those that require careful management due to pharmacodynamic (PD) or pharmacokinetic (PK) effects.

Contraindicated Combinations and Timing Rules

The medicine is formally prohibited for co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, due to an increased risk of severe adverse effects. High-dose acetylsalicylic acid (Aspirin) is also contraindicated. When co-administered with low-dose non-enteric coated aspirin, a timing separation is specified: Bifen must be taken at least 8 hours before or 30 minutes after the aspirin dose to mitigate interference with its antiplatelet effect.

Clinically Significant Interactions

Interaction Mechanism Interacting Substance Categories Official Outcome Description
PK Exposure Modification Lithium, Methotrexate, Cardiac Glycosides Decreased clearance, resulting in increased plasma concentrations of the co-administered drug.
PD Risk Enhancement Anticoagulants, Oral Corticosteroids, SSRIs Enhanced effects (Anticoagulants) or increased risk of gastrointestinal bleeding (Corticosteroids, SSRIs).
Therapeutic Efficacy Diminishment Antihypertensives (ACE Inhibitors, Diuretics) Reduction in the blood pressure-lowering or diuretic effect.

Other Interaction Notes The risk of stomach bleeding is documented as higher when Bifen is combined with alcohol, particularly with chronic, heavy consumption. Interactions, especially those impacting renal function, are noted to be more significant in elderly patients and those with existing compromised renal function.

Mechanism of Action

Core Action: Non-Selective COX Enzyme Inhibition

Bifen primarily acts by reversibly inhibiting both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular blockade interrupts the fundamental biological cascade that converts Arachidonic Acid into prostaglandins, which are key local mediators of the body's inflammatory and thermoregulatory responses.


Pathway Effect: Modulating Prostaglandin-Mediated Signaling

The resulting drop in prostaglandin levels, particularly PGE2, modulates relevant physiological systems in two ways. Peripherally, it lowers the sensitization of nociceptors (pain-sensing neurons) at the site of injury; centrally, it resets the prostaglandin-driven elevation of the body’s thermal set-point within the hypothalamus. This suppression of the prostaglandin message initiates the compound's observable physiological consequences.


Mechanistic Constraints

The compound's mechanism of action is intrinsically linked to the prostaglandin pathway, meaning its mechanism of action is constrained to physiological responses substantially mediated by these molecules. Furthermore, its reversible binding to the COX enzymes dictates that the inhibition is temporary, requiring sustained presence of the compound to maintain the enzymatic inhibition.

Dosage and Administration Information

Bifen, which contains the active ingredient Ibuprofen, is used according to specific administration protocols. The primary method of administration is the oral route, utilizing tablets, capsules, or oral suspension. Specialized intravenous (IV) formulations are also approved for use in certain clinical settings, such as for the management of acute pain in a supervised environment or for specific neonatal applications.

Official Dosing and Frequency

Usage Pattern Adult Dosing (Oral) Frequency
Acute Relief (Short-term) 200 mg to 400 mg per dose Every 4 to 6 hours as needed
Chronic Conditions 1200 mg to 3200 mg per day Administered in 3 or 4 divided doses

All use must adhere to the principle of employing the lowest effective dose for the shortest duration necessary. For non-prescription acute use, the treatment course is generally limited to a maximum of 10 days. The maximum prescription daily dose for adults is typically 3200 mg.

Administration Context and Adjustments

Oral doses may be taken with food or milk to aid gastrointestinal tolerance. For liquid suspensions, the product must be shaken well and the dose accurately measured with the provided device. Pediatric administration is strictly based on body weight (mg/kg), defining the required milligram amount per dose. Older adults are advised to begin with the lowest possible dose due to heightened physiological sensitivity.

Recent Clinical Evidence

Research evidence / Overview of Studies for Bifen

The evidence base for Bifen (Ibuprofen) is founded upon numerous studies, including large numbers of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies are used to explore how symptoms change over time in observed populations. The findings described below reflect patterns measured during these studies, not personal outcomes or specific advice.


Evidence for Use in Acute Mild-to-Moderate Pain

The evidence base is founded upon numerous studies, with many short-term RCTs applied in studies examining patient-reported experiences related to physical discomfort. These trials were primarily designed to monitor short-term symptom changes in conditions associated with acute or disruptive episodes, such as headache, dental pain, and musculoskeletal discomfort.

Studies reported measurable differences in Pain Intensity scores between subjects receiving Bifen and those receiving a neutral substance (placebo). Research describes patterns related to the Time to Measurable Change in Pain that were observed across various pain models. Trials reported a lower need for follow-up pain medication in the Bifen-receiving groups compared to control groups in some studies.

What remains uncertain:

Although the evidence is considered high-certainty in research that compared Bifen to placebo in acute pain settings, the results apply only to the populations studied and only for very short-term follow-up durations. Comparative evidence finding an advantage over other common analgesics is limited and may be heterogeneous.


Evidence for Use in Managing Symptoms of Inflammation and Stiffness

Bifen was studied for its role in research exploring symptoms of chronic inflammatory conditions and stiffness. Research examined conditions such as rheumatoid arthritis and osteoarthritis, which are marked by functional limitations and periods of heightened symptom activity, as well as primary dysmenorrhea (menstrual cramping).

The studies monitored changes in patient-reported outcomes related to functional imbalance, such as measures of stiffness and pain, often tracked using specific functional mobility scales in arthritis trials. Research highlights changes measured during the study period for subjects with chronic conditions, with findings describing patterns observed in the studies related to symptomatic change.

What remains uncertain:

Research exploring chronic symptoms is limited when exploring long-term outcomes. The follow-up durations for many trials were medium-term (several months) and do not provide extensive data on the agent’s influence on disease progression over many years. Data for certain groups, particularly those with multiple coexisting conditions, remains insufficient.


Evidence for Antipyretic Action (Fever Reduction)

Bifen’s antipyretic effects (on fever) was examined in research exploring temporary physiological imbalance. Research describes a pattern of a measurable decrease in body temperature across diverse patient age groups following administration during episodes of acute fever. Comparative data show patterns related to temperature reduction that were observed in trials against other agents. The reported data describes a measurable physiologic effect on temperature regulation in febrile states.


What Remains Uncertain About Bifen’s Clinical Evidence

Research is ongoing, but key limitations persist. There is limited information for long-term outcomes that track disease modification rather than just temporary symptom change. Comparative evidence showing an advantage over other non-steroidal anti-inflammatory drugs (NSAIDs) remains mixed. Additionally, data for certain groups, such as patients with specific coexisting diseases, remains insufficient, meaning that subgroup findings are uncertain.

Key Studies & References

  1. Ibuprofen: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Bifen (FAQ)


Q: How quickly should I expect Bifen to start working?

A: Official product information indicates that Bifen's active ingredient, ibuprofen, is rapidly absorbed after oral administration. Peak concentrations, which typically correspond with the highest level of the medicine in the bloodstream, are generally reached in one to two hours. This absorption time frame is often associated with the onset of effect in studies, but individual response times may vary.


Q: How long does Bifen stay in your system after you stop taking it?

A: The elimination half-life of Bifen (ibuprofen) is consistently reported to be approximately 1.8 to 2 hours in healthy adults. Based on its half-life, the medicine is expected to be largely cleared from the body within about 12 hours after the last dose. This short duration dictates the need for regular dosing to sustain its physiological effects.


Q: Is it normal to feel a bit nauseous when first starting Bifen?

A: Nausea is classified in regulatory documents as a common adverse effect, frequently related to the digestive system. Official guidance suggests that oral doses may be taken with food or milk to help reduce the incidence of gastrointestinal upset.


Q: What are the most commonly reported side effects of Bifen?

A: According to official product labeling, the most commonly reported adverse effects typically include gastrointestinal issues, such as nausea, vomiting, dyspepsia (indigestion), and abdominal pain. Nervous system effects like headache and dizziness are also frequently noted.


Q: Can Bifen cause changes in sleep patterns?

A: Official labeling for Bifen's active ingredient, ibuprofen, reports common effects on the central nervous system like headache and dizziness. However, common changes to sleep patterns, such as insomnia or altered sleep cycles, are not explicitly listed as a frequent adverse reaction in major regulatory documents.


Q: Are there any long-term side effects associated with Bifen use?

A: Regulatory warnings indicate that the use of NSAIDs over prolonged periods or at high doses may increase the risk of serious side effects. These include serious cardiovascular events (such as heart attack or stroke) and serious gastrointestinal events (like bleeding or ulceration). Treatment should adhere to the lowest effective dose for the shortest duration necessary.


Q: Do you have to take Bifen with food, or does it matter?

A: Official product information advises that oral doses of Bifen may be taken with food or milk. This action is suggested as a way to help reduce the risk of gastrointestinal irritation or upset and improve general tolerance.


Q: What happens if I miss a dose of Bifen?

A: If a dose is missed, patient information typically advises that the dose may be taken as soon as it is remembered. However, if the next scheduled dose is soon, the missed dose may be skipped, as patient information advises against taking two doses at one time to make up for a missed dose.


Q: Can I drink coffee or caffeine while taking Bifen?

A: Official drug interaction databases generally do not report a specific interaction between routine amounts of caffeine and ibuprofen. However, caution is always warranted, and it is important to check the ingredients of any co-administered products, especially combination medicines.


Q: Are there any specific foods or supplements I should avoid while on Bifen?

A: Regulatory warnings highlight the interaction with alcohol, as co-administration may increase the risk of serious stomach bleeding, particularly with chronic, heavy consumption. Official documents also advise caution regarding supplements with antiplatelet activity, such as ginkgo or garlic.


Q: Does Bifen interact with birth control pills?

A: Drug interaction databases suggest that ibuprofen, especially when used regularly or long-term, may affect blood potassium levels if combined with specific types of oral contraceptives. This potential interaction is noted in regulatory databases, especially for specific contraceptive ingredients, but detailed clinical management is not specified.


Q: Does Bifen affect my ability to drive or operate machinery?

A: Bifen is associated with central nervous system effects such as dizziness and headache. Official guidance indicates that patients who experience these effects should use caution regarding activities that require alertness, such as driving or operating machinery.


Q: Is it possible for Bifen to cause skin rash or hives?

A: Yes, official labeling notes that Bifen's active ingredient, ibuprofen, can cause a severe allergic reaction. This may include visible signs like skin reddening, hives, rash, or blisters. If signs of an allergic reaction appear, patients are advised in official warnings to seek immediate medical help.


Q: Does Bifen cause weight gain or loss?

A: While regulatory labeling does not classify significant weight changes as a common side effect, the drug is associated with side effects such as fluid retention and edema (swelling). This known physiological effect should be considered in high-risk patient populations.


Q: Can Bifen be taken for an extended period of time?

A: For non-prescription acute use for pain and fever, treatment duration is generally limited to 10 days according to patient information. However, Bifen may be used for managing symptoms of chronic conditions for longer periods under the direct supervision of a healthcare professional.


Q: Is Bifen safe for children or teenagers?

A: Bifen's active ingredient is permitted for pediatric populations, typically starting from 6 months of age. Dosage for children is determined based on body weight (mg/kg) using the appropriate formulation, as detailed in product labeling for pediatric populations.


Q: Can Bifen affect the results of lab tests?

A: Ibuprofen can be associated with borderline elevations of liver tests and may sometimes cause anemia or affect platelet aggregation (clotting). Additionally, its pain-reducing activity may diminish the utility of diagnostic signs. If this occurs, regulatory patient labeling provides guidance for follow-up.


Q: Is a metallic taste in the mouth a known side effect of Bifen?

A: A metallic taste in the mouth is not explicitly listed among the officially classified common or serious adverse reactions in the main regulatory documents for Bifen's active ingredient.


Q: Is Bifen commonly prescribed in combination with other drugs?

A: Ibuprofen has documented clinically significant interactions with several drug categories, including blood pressure medicines, anticoagulants, and oral corticosteroids. Due to these potential interactions, any co-administration is noted as requiring careful professional monitoring.


Q: What are the high-level contraindications for Bifen?

A: Official labeling states Bifen must not be used by people with a history of active stomach bleeding or peptic ulceration or those with severe heart, kidney, or liver failure. Official labeling also specifies contraindications for patients with a known allergy to NSAIDs or those receiving treatment for pain following coronary artery bypass graft (CABG) surgery.


Q: Can Bifen be split or crushed, or must it be swallowed whole?

A: While regulatory information does not strictly prohibit splitting or crushing immediate-release tablets, it specifies that certain formulations, such as modified-release or delayed-release tablets, must be swallowed whole to ensure the medicine's proper absorption and function are maintained.


Q: What are the signs that Bifen is not working for me?

A: Regulatory patient labeling suggests Bifen may not be providing adequate relief if the pain or fever gets worse or if the symptoms do not improve within 3 days for fever or 7 days for pain. If this occurs, regulatory patient labeling provides guidance for follow-up.


Q: Is Bifen widely used outside of the US?

A: Yes, Bifen's active ingredient, ibuprofen, is recognized and regulated by major international health authorities across Europe (EMA), Canada (Health Canada), and Australia (TGA). This widespread authorization confirms its use and recognition in various international markets.


Q: Are generic versions of Bifen as effective as the brand name?

A: Regulatory bodies like the FDA require that generic drugs meet rigorous standards for quality, strength, purity, and bioequivalence (meaning they work the same way) as the brand-name product. This ensures that generic versions are expected to have the same clinical effect.


Q: Do alcohol and Bifen have a serious interaction?

A: Yes, regulatory warnings specify that combining Bifen with alcohol may increase the risk of serious gastrointestinal bleeding. This risk is considered particularly elevated with chronic and heavy alcohol consumption.


Q: Is it important to monitor blood pressure while taking Bifen?

A: Official warnings state that NSAIDs can potentially cause new hypertension (high blood pressure) or worsen existing hypertension. For this reason, patient labeling advises that blood pressure monitoring is recommended during the initiation of NSAID treatment and throughout the course of therapy.

How should Bifen be stored and disposed of?

How to Store and Dispose of Bifen?

Bifen must be stored and disposed of strictly according to regulatory guidelines to prevent contamination and exposure. The product should be kept in its original container, tightly closed, and stored in a cool, dry, well-ventilated, and secured area.

Keep Bifen out of reach of children and animals and away from direct sunlight, heat, and incompatible substances like strong acids. It must not be stored near food or feed items. After partial use, ensure the lid is replaced and closed tightly.

Disposal of Bifen and its containers must comply with Federal, state, and local laws and regulations. Do not contaminate water sources, as this pesticide is extremely toxic to fish and aquatic invertebrates. Improper disposal of excess product is a violation of Federal Law; contact the appropriate environmental agency for guidance on hazardous waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bifen found in:

A-Z Index: